Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 4/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 14/20 | 0.44 |
| ▸ | DHPS | P49366 | 1/20 | 0.42 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3565002 | 0.91 | HDAC2 (0.53) | HDAC2HDAC1DHPSOPRM1 | |
| SCHEMBL5051806 | 0.84 | HDAC1 (0.57) | HDAC2HDAC1DHPSMEN1USP2 | |
| SCHEMBL3577453 | 0.84 | HDAC2 (0.47) | HDAC2HDAC1DHPSOPRM1 | |
| SCHEMBL3563743 | 0.83 | HDAC2 (0.54) | HDAC2HDAC1HDAC3NCOR2 | |
| SCHEMBL3568753 | 0.82 | HDAC2 (0.53) | HDAC2HDAC1DHPSOPRM1 | |
| SCHEMBL3565882 | 0.82 | HDAC2 (0.53) | HDAC2HDAC1OPRM1 | |
| SCHEMBL3570546 | 0.82 | HDAC2 (0.53) | HDAC2HDAC1HDAC3 | |
| SCHEMBL3814883 | 0.81 | HDAC1 (0.60) | HDAC2HDAC1DHPS | |
| SCHEMBL3567588 | 0.81 | HDAC2 (0.46) | HDAC2HDAC1 | |
| SCHEMBL3573817 | 0.81 | HDAC2 (0.52) | HDAC2HDAC1HDAC3NCOR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7772238-B2 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | claimed |
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | claimed |
| EP-1874755-A2 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | Merck & Co., Inc. (US) | 2008-01-09 | — | — | EP | claimed |
| WO-2006115835-A2 | BENZOTHIOPHENE HYDROXAMIC ACID DERIVATIVES | MERCK & CO., INC. (US) | 2006-11-02 | — | — | WO | claimed |
| US-7772238-B2 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME CORP. (US) | 2010-08-10 | — | — | US | disclosed |
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | MERCK SHARP & DOHME LLC | 2009-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090069391-A1 | Benzothiophene hydroxamic acid derivatives | BRDT, HDAC5, BRPF3 | HDAC2 9/4885HDAC1 4/4885DHPS 1981/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.